Pharmaceutical-grade liraglutide active pharmaceutical ingredient is released as a lyophilized white to off-white powder intended for formulation into injectable and oral solid dosage presentations, including tablet, capsule, and granule intermediates. The product is identified by the USAN/INN designation liraglutide and CAS registry number 204656-20-2. The molecule is a 31-residue acylated analogue of human GLP-1(7-37) with a molecular formula C172H265N43O51 and a monoisotopic molecular weight near 3751.20 g/mol. Because the generic API is not assigned a universal commercial model, procurement specifications refer to manufacturer lot code, container/closure configuration, fill quantity, and the current pharmacopoeial monograph. Primary packaging for the API is generally a Type I borosilicate glass vial with a butyl rubber stopper and aluminium flip-off seal, or a pharmaceutical-grade PETG/LDPE container, enclosed in a secondary barrier with desiccant and oxygen absorber where stability data require.

Long-term storage of the lyophilized powder is recommended at -20 °C ± 5 °C in a desiccated, light-protected environment. The powder is hygroscopic and should be equilibrated inside a dry atmosphere before weighing. Once reconstituted, liraglutide solution should be used promptly and not subjected to repeated freeze-thaw cycles; peptide aggregation can occur at air-liquid interfaces and under thermal or shear stress. The API is supplied for pharmaceutical development and commercial manufacturing under cGMP; it is not intended for direct patient administration without further formulation and quality release.

What distinguishes liraglutide from native GLP-1 and other marketed GLP-1 receptor agonists?

Native human GLP-1(7-37) exhibits a circulating half-life below 2 min because of rapid N-terminal cleavage by dipeptidyl peptidase IV and renal clearance. Liraglutide is engineered to overcome this limitation through two controlled structural changes: a C16 palmitic acid is attached through a γ-L-glutamoyl spacer to lysine at position 26, and arginine is substituted at position 34. The resulting peptide has a subcutaneous half-life of approximately 13 h, enabling once-daily injection. Its sequence identity to human GLP-1 is 97%, compared with 53% for exenatide and 94% for semaglutide. The acylation also promotes reversible albumin binding and delayed migration from the subcutaneous depot, which reduces peak plasma concentration and sustains exposure.

The downstream difference is not limited to dosing frequency. The acylated peptide has greater tendency to self-associate and to bind hydrophobic surfaces than unmodified GLP-1, affecting filter selection, container compatibility, and assay recovery. The table below summarizes comparative data relevant to formulation route selection.

Lot release for pharmaceutical-grade liraglutide is performed against a method panel aligned with ICH Q3C, ICH Q3D, and current pharmacopoeial chapters. Reversed-phase HPLC on a C18 column with UV detection at 215 nm or 220 nm is used for assay and related-substances; liquid chromatography–mass spectrometry with peptide mapping confirms primary sequence and the palmitoyl acylation site. Karl Fischer titration under USP <921> Method Ic determines residual moisture, while headspace gas chromatography under USP <467> controls residual solvents. Bacterial endotoxin is measured by kinetic chromogenic LAL according to USP <85> or Ph. Eur. 2.6.14. Elemental impurities are controlled under ICH Q3D using the procedures of USP <232> and <233>. Total aerobic microbial count and specified organisms follow USP <61> and <62>. Each batch is reviewed against 21 CFR 210/211 cGMP requirements before release.

Injectable formulation parameters and sterile filtration boundaries

For injectable formulations, liraglutide API is dissolved in water for injection or a suitable buffer and pH-adjusted with dilute hydrochloric acid or sodium hydroxide to the target product specification. Terminal steam sterilization is not recommended because the acylated peptide is sensitive to heat-induced aggregation and fibril formation. Aseptic filtration through a validated 0.22 µm membrane is the standard sterilizing route. Low-protein-binding polyethersulfone or polyvinylidene fluoride membranes are preferred, but filter adsorption must be evaluated at small scale because peptide loss is concentration-dependent and can be significant without membrane saturation. Process development should use size-exclusion HPLC to monitor soluble aggregate formation and dynamic light scattering to detect subvisible particles in parallel with compendial light obscuration testing.

Compounding and filling are performed in an ISO 14644-1 Class 5 environment using single-use or passivated stainless steel equipment. Low-shear mixing with magnetic or overhead impellers is used to reduce interfacial denaturation. Approved reference injection products have been formulated as solutions at 6 mg/mL in prefilled pen injectors; however, the final concentration, buffer, tonicity agent, and preservative are product-specific. Multidose injection products containing liraglutide require preservative effectiveness testing under USP <51> or Ph. Eur. 5.1.3. Pen injector dose accuracy and function are evaluated under ISO 11608-1, and container closure integrity is verified under USP <1207>. Subvisible particulate matter is controlled under USP <788>, and visual inspection is performed according to USP <1790>.

During scale-up, pH drift and protein concentration at the filter surface are monitored because concentration polarization can promote aggregation. In-use stability studies should include exposure to room temperature after first use and simulated dose administration. Any change in buffer strength, ionic strength, or preservative level requires forced degradation comparison because liraglutide aggregation kinetics depend on pH, temperature, and ionic environment. On commercial isolator-based aseptic filling lines, silicone oil from prefilled syringe plungers can interact with the acylated peptide and form subvisible particles; compatibility studies with the specific primary packaging are therefore required. Published data for generic liraglutide injection compounding using non-reference excipients is limited, so each composition must be qualified experimentally.

Oral tablet, capsule, or granule formulation containing liraglutide API is developmentally distinct from injectable formulation because gastrointestinal peptidases, mucus turnover, and the epithelial barrier limit absorption of a 3751.20 g/mol peptide. Published data for an approved oral liraglutide tablet or capsule is limited. Formulators therefore treat the route as investigational and justify the selected absorption-enhancement technology using in vitro permeation, enzyme inhibition, and pharmacokinetic data. The oral peptide strategy used for semaglutide, which employs the absorption enhancer sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, demonstrates that oral GLP-1 receptor agonist delivery is technically feasible, but direct transfer to liraglutide cannot be assumed without comparative evaluation because the fatty acid, spacer, and half-life differ.

In solid dosage development, the API is typically pre-blended with a carrier to avoid low-dose segregation. Direct compression and dry granulation are investigated before wet granulation because water can mobilize peptide aggregates and induce chemical degradation. If roller compaction is used, ribbon density and mill screen size are adjusted to preserve particle size distribution and flow. For capsules, triboelectrification and powder adhesion to metal pins or dosators are common failure modes observed on production equipment; anti-static control and surface passivation are used only when compatibility studies exclude peptide adsorption. Extraction recovery from tablet or capsule matrices must be verified because liraglutide can bind to magnesium stearate, croscarmellose sodium, or high-surface-area silicon dioxide during sample preparation. A common analytical approach uses acidified acetonitrile-water mixtures with an internal standard and sonication under chilled conditions, followed by filtration through a low-protein-binding membrane. Method validation follows ICH Q2(R1) and USP <1225>.

When oral solid dosage development adds particle-size and moisture-control requirements

Low-dose oral solid dosage forms containing liraglutide API require strict control of particle size distribution to meet content uniformity. The lyophilized material should be sieved or milled under low-humidity conditions. If direct compression is selected, ordered mixing with a coarse carrier such as lactose monohydrate can reduce segregation; a carrier D50 in the range of 60–100 µm is common for low-dose direct compression, but optimum blending time must be established. Overmixing can lead to API adhesion to blender walls and reduced assay recovery. Tablets are tested for content uniformity according to USP <905>, friability according to USP <1216>, and disintegration according to USP <701>.

Moisture protection is critical for oral solids. The granulation end point should be controlled with in-line near-infrared analysis, and residual moisture after drying should remain below the limit derived from ICH Q1A stability data for the specific formulation. Aqueous wet granulation should be avoided where possible; if necessary, granulation fluid flow rate and inlet air dew point in the fluid-bed dryer are controlled to avoid overwetting. Dry granulation via roller compaction is preferred because it avoids adding moisture while producing granules suitable for capsule filling or tablet compression. Granule particle size after dry granulation is controlled with sieve analysis under USP <786>.

Capsule filling on dosator or tamping-pin machines can show fill weight variability if the powder exhibits static charge or if the API adheres to stainless steel contact parts. The formulation may require a glidant such as colloidal silicon dioxide below 1.0% w/w, but adsorption studies must be performed because high-surface-area silicas can bind peptides and reduce in vitro dissolution. Tablet compression dwell time and turret speed should be limited to avoid frictional heating beyond the stability threshold observed in forced degradation studies. Content uniformity and blend homogeneity are evaluated at production scale with stratified sampling using powder blend sampling thieves and HPLC assay.

Incompatibility studies for liraglutide API should exclude strong oxidising agents, strongly alkaline conditions above the pH stability range, and high concentrations of primary amines where hydrolytic degradation of the acylated lysine side chain can occur. Trace Fe(III) and Cu(II) from equipment erosion or water supply can catalyse oxidation of tryptophan-containing peptide structures; therefore, water for injection should meet conductivity and total organic carbon limits under USP <645> and <643>. Chelating agents may be evaluated only if formulation compatibility data demonstrate that they do not alter the peptide’s higher-order structure or binding properties. Lyophilized API should not be stored near strong oxidising agents or under uncontrolled high-humidity conditions. Because the material is a peptide, any change in container closure system should be evaluated with extractables and leachables studies under USP <1663> to ensure that elastomer-derived compounds do not promote aggregation or covalent adduct formation.